Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Consulting agrmnt
Director departure
Appointed director
|
|
ORGANOVO HOLDINGS, INC. (ONVO)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 05/31/2018 |
8-K
| Quarterly results |
| 02/08/2018 |
8-K
| Quarterly results |
| 11/09/2017 |
8-K
| Quarterly results |
| 08/09/2017 |
8-K
| Quarterly results |
| 06/07/2017 |
8-K
| Form 8-K - Current report |
| 02/09/2017 |
8-K
| Form 8-K - Current report |
| 11/03/2016 |
8-K
| Form 8-K - Current report |
| 08/04/2016 |
8-K
| Quarterly results |
| 06/09/2016 |
8-K
| Form 8-K - Current report |
| 02/08/2016 |
8-K
| Quarterly results |
| 11/09/2015 |
8-K
| Quarterly results |
| 08/10/2015 |
8-K
| Quarterly results |
| 06/09/2015 |
8-K
| Quarterly results |
| 02/09/2015 |
8-K
| Quarterly results |
| 11/10/2014 |
8-K
| Quarterly results|
Docs:
|
"Organovo Holdings, Inc. Reports Second Quarter Results SAN DIEGO, Nov. 10, 2014 /PRNewswire/ — Organovo Holdings, Inc. , a three-dimensional biology company focused on delivering pioneering 3D bioprinting technology, has reported its second quarter, fiscal 2015, results. Keith Murphy, chairman and chief executive officer of Organovo, commented on the results: “Last quarter Organovo demonstrated that our exVive3D™ Human Liver Model is clearly able to detect drug-induced liver injury that other methods in the past failed to predict. With that data in hand we are ready to initiate the commercialization of our 3D Liver Tissue before the end of November, 2014. Our achievements in the development of this technology were honored this past quarter in multiple ways, including through selection of o..." |
|
| 08/12/2014 |
8-K
| Quarterly results |
| 06/12/2014 |
8-K
| Quarterly results |
| 02/07/2014 |
8-K
| Quarterly results|
Docs:
|
"Organovo Reports Q3 Fiscal 2014 Results, Provides Business Update SAN DIEGO, February 7, 2014 / PRNewswire/ — Organovo Holdings, Inc. , a three-dimensional biology company focused on delivering breakthrough 3D bioprinting technology, has reported its third quarter results and provided highlights of its recent activities. Keith Murphy, chairman and chief executive officer of Organovo, commented on the results. “The quarter continues our progress throughout our scientific, operational and business development activities. Our progress in the development of 3D Liver tissues continues to be ahead of plan, highlighted by the demonstration of 40 days of characteristic liver activity and additional evidence of appropriate response to known hepatotoxic insults. We remain on-track for releasing our ..." |
|
| 11/12/2013 |
8-K
| Quarterly results|
Docs:
|
"ORGANOVO REPORTS Q2 FISCAL 2014 RESULTS, PROVIDES BUSINESS UPDATE November 12, 2013 SAN DIEGO, Organovo Holdings, Inc. , a three-dimensional biology company focused on delivering breakthrough 3D bioprinting technology, has reported its second quarter results and provided highlights of its recent activities. Keith Murphy, Chairman and Chief Executive Officer of Organovo, commented on the results, “The quarter was marked by excellent progress across financial, operational and business development areas. Our progress in the development of 3D liver tissues has been exceptional, including the demonstration of 40 days of viability and functionality, and we remain on-track for releasing our first commercial liver toxicity assay product in calendar 2014. Our new strategic agreements are expected t..." |
|
| 03/18/2013 |
8-K
| Form 8-K - Current report |
| 11/16/2012 |
8-K
| Form 8-K - Current report |
|
|